Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial
作者
Sven Schinner
出处
期刊:Yearbook of Endocrinology日期:2011-01-01卷期号:2011: 3-4被引量:9